AERIE PHARMACEUTICALS INC
DelistedCIK 1337553fmd_1HKSY3FC2MWZ54C2QQENKHRHJ2Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2005 to Sep 30, 2022, 50 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | 24 | 70 | 83 | 194 |
| Cost of revenue | – | – | – | – | 0 | 0 | 1 | 5 | 25 | 27 |
| Net interest income | – | – | – | – | 1 | 2 | 3 | 3 | 2 | 0 |
| Gross profit | – | – | – | – | 0 | 0 | 24 | 65 | 58 | 167 |
| Research and development | 9 | 12 | 30 | 44 | 52 | 72 | 86 | 91 | 74 | 76 |
| Selling, general and administrative | – | – | – | 31 | 35 | 57 | 121 | 138 | 137 | 138 |
| Total operating expenses | – | – | – | 75 | 97 | 146 | – | – | – | – |
| Operating income | (14) | (22) | (50) | (75) | (97) | (146) | (210) | (187) | (156) | (46) |
| Interest expense | 0 | 4 | 1 | 2 | 3 | – | 3 | 15 | 27 | 29 |
| Other non-operating income (expense) | (1) | (9) | 2 | 1 | (2) | (1) | (23) | (12) | (22) | (28) |
| Income before taxes | – | (31) | (48) | (74) | (99) | (147) | (233) | (200) | (178) | (74) |
| Income tax expense | – | 0 | 0 | 0 | 0 | (2) | 0 | (0) | 5 | 1 |
| Net income from continuing operations | – | (31) | (48) | (74) | (99) | (145) | (233) | (200) | (183) | (75) |
| Net income | (15) | (31) | (48) | (74) | (99) | (145) | (233) | (200) | (183) | (75) |
| Net income to common shareholders | (16) | (32) | (48) | (74) | (99) | – | – | – | – | – |